Short Interest in bioAffinity Technologies, Inc. (NASDAQ:BIAF) Decreases By 36.5%

bioAffinity Technologies, Inc. (NASDAQ:BIAF) was the target of a large decrease in short interest in February. As of February 15th, there was short interest totalling 251,900 shares, a decrease of 36.5% from the January 31st total of 396,800 shares. Based on an average daily trading volume, of 177,700 shares, the days-to-cover ratio is presently 1.4 days. Approximately 2.7% of the shares of the company are short sold.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in bioAffinity Technologies stock. Sheaff Brock Investment Advisors LLC boosted its stake in bioAffinity Technologies, Inc. (NASDAQ:BIAF) by 131.5% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 46,304 shares of the company’s stock after buying an additional 26,304 shares during the period. Sheaff Brock Investment Advisors LLC owned 0.30% of bioAffinity Technologies worth $42,000 at the end of the most recent quarter. 1.64% of the stock is currently owned by institutional investors and hedge funds.

bioAffinity Technologies Stock Performance

BIAF traded down $0.09 during trading hours on Monday, hitting $0.41. The company’s stock had a trading volume of 154,657 shares, compared to its average volume of 168,253. The company has a 50-day simple moving average of $0.79 and a 200 day simple moving average of $1.25. The company has a current ratio of 1.02, a quick ratio of 1.01 and a debt-to-equity ratio of 0.18. The firm has a market capitalization of $6.39 million, a PE ratio of -0.50 and a beta of 2.95. bioAffinity Technologies has a fifty-two week low of $0.40 and a fifty-two week high of $3.62.

About bioAffinity Technologies

bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level.